Lenskart IPO Frenzy: Sky-High Valuation Meets Surging Demand – Will Investors See Big Gains?

Lenskart IPO Allotment Today (Nov 6): GMP at ₹35–₹45, how to check status on MUFG Intime/BSE/NSE, listing on Nov 10

New Delhi | November 6, 2025 — Updated through the day


TL;DR (What changed today)

  • Allotment: Basis of allotment is slated to be finalised today, Thursday, November 6; demat credit/refunds expected to begin November 7. [1]
  • GMP today: Unofficial grey-market premium hovered between ₹35 and ₹45 during the day, implying a tentative listing range of ~₹437–₹447 vs the upper price band of ₹402. (GMP is not an official indicator.) [2]
  • Listing date: Shares are expected to list on Monday, November 10, on both BSE and NSE. [3]
  • Demand snapshot (final day): Overall subscription 28.26×; QIB 40.35×, NII 18.23×, Retail 7.54×. [4]

Lenskart IPO GMP today (Nov 6)

Market trackers reported the Lenskart IPO GMP at ₹35 in the morning, implying a ~₹437 indicative price (≈8–9% over the ₹402 upper band). By late afternoon, some trackers cited ₹45, hinting at ~₹447 (≈11% over ₹402). Remember, GMP is an unregulated, unofficial signal and can change quickly. [5]

How to check Lenskart IPO allotment status (when the basis is finalised)

You can verify status on any one of these three official portals:

  1. Registrar — MUFG Intime India (formerly Link Intime)
    • Select “Lenskart Solutions Limited”
    • Search by PAN/Application No./DP ID-Client ID/Account No. [6]
  2. BSE
    • Issue type: Equity → Issue name: Lenskart Solutions Limited → Enter Application No. or PAN. [7]
  3. NSE
    • Go to IPO bid verification → Choose “Lenskart Solutions Limited” → Enter PAN + Application No. [8]

Business dailies also carried the direct links to these pages for convenience if you prefer to navigate via media references. [9]

Tip: If you’re not allotted, brokers expect refund initiation from Nov 7; check with your bank/broker if you don’t see a reversal or ASBA release after that. [10]

Key IPO numbers at a glance

  • Issue size: ₹7,278 crore (₹2,150 crore fresh + ₹5,128 crore OFS)
  • Price band: ₹382–₹402 per share
  • Lot size (retail):37 shares per lot
  • Subscription (final day, Nov 4):28.26× overall (QIB 40.35×, NII 18.23×, Retail 7.54×)
  • Expected listing:Nov 10 (Mon) on BSE & NSE
    These figures were reiterated across today’s allotment-day coverage and live blogs. [11]

Should you expect listing gains?

The day’s GMP band (₹35–₹45) implies an 8–11% premium over the upper price band, but the signal softened vs earlier peaks as trackers flagged volatility heading into allotment. High subscription ≠ guaranteed pop; today’s commentary emphasised valuation sensitivity despite strong brand metrics. [12]

Why there’s so much buzz (and caution)

Beyond market blogs, the IPO also spilled into mainstream culture. Actor Soha Ali Khan posted a widely shared explainer reminding retail investors that IPOs aren’t “get-rich-by-next-Friday” schemes—brand strength doesn’t override valuation and risk. It’s a timely reminder on allotment day. [13]

What happens next?

  • Nov 6 (today): Basis of allotment to be finalised.
  • Nov 7 (Fri): Refund initiation/ASBA release; demat credits for successful applicants expected to start.
  • Nov 10 (Mon): Trading debut on BSE/NSE.
    Timelines above reflect today’s newsroom guidance; always reconfirm with your broker back office. [14]

FAQ

Is MUFG Intime India the registrar?
Yes. Multiple outlets list MUFG Intime India Pvt. Ltd. as registrar (the entity formerly known as Link Intime). [15]

What were the final-day subscription numbers?
28.26× overall; QIB 40.35×, NII 18.23×, Retail 7.54×. [16]

What’s the indicative listing price based on today’s GMP?
Roughly ₹437–₹447 versus the ₹402 upper band—purely indicative, not official pricing guidance. [17]

When will Lenskart list?
Bourses and media reports peg Monday, Nov 10 for the listing. [18]


Editor’s note (investor disclosure)

Grey-market chatter is unofficial and volatile. This article is for information only and is not investment advice. Please consult a SEBI-registered adviser for personalised guidance.


Sources used today (Nov 6): Live blogs and explainers tracking allotment, GMP and dates, including Mint, Moneycontrol, Economic Times, Business Standard, and India Today; plus a cultural explainer from TOI (Entertainment).

  • GMP & allotment-day updates, implied listing math: Mint live/allotment explainer. [19]
  • Morning GMP print & implied price: ET live blog. [20]
  • Allotment timing, refund start (Nov 7), listing date (Nov 10), registrar steps: Moneycontrol live & explainer. [21]
  • Where to check allotment (BSE/NSE/registrar): Business Standard note. [22]
  • Softening GMP narrative & key offer terms: India Today coverage. [23]
  • Cultural context/caution for retail investors: TOI (Entertainment) on Soha Ali Khan’s IPO explainer. [24]
PhysicsWallah IPO | Orkla IPO Listing Strategy | Groww IPO | Lenskart IPO | Jayesh Khatri

References

1. www.livemint.com, 2. m.economictimes.com, 3. www.moneycontrol.com, 4. www.moneycontrol.com, 5. m.economictimes.com, 6. www.moneycontrol.com, 7. www.livemint.com, 8. www.livemint.com, 9. www.business-standard.com, 10. www.moneycontrol.com, 11. www.moneycontrol.com, 12. www.indiatoday.in, 13. timesofindia.indiatimes.com, 14. www.moneycontrol.com, 15. www.moneycontrol.com, 16. www.moneycontrol.com, 17. m.economictimes.com, 18. www.moneycontrol.com, 19. www.livemint.com, 20. m.economictimes.com, 21. www.moneycontrol.com, 22. www.business-standard.com, 23. www.indiatoday.in, 24. timesofindia.indiatimes.com

Stock Market Today

  • Stocks set for tiny gains ahead of the open on mixed earnings
    November 6, 2025, 10:54 AM EST. U.S. stock futures point to tiny gains ahead of the opening bell as investors digest mixed corporate earnings. Traders weigh stronger results from some companies against softer reports and scrutinize outlooks, margins, and guidance. A cautious tone persists as markets await a light but potentially volatile session, with attention on how earnings shape expectations for the broader market and the upcoming data.
  • NYSE Pre-Market Update: Evommune & Aeromexico IPOs Begin Trading; Altice Rename to Optimum, Ticker OPTU
    November 6, 2025, 10:53 AM EST. Today's NYSE pre-market update shows stocks little changed after a rebound led by AI names. Oracle rose nearly 1% on the session. The spotlight: Evommune debuts on the NYSE after pricing at $16 a share, raising $150 million to advance treatments for chronic inflammatory diseases like eczema and hives. Grupo Aeromexico also priced its IPO at $19, raising about $223 million as it rounds into service for global connections from Mexico. Altice USA will rename to Optimum Communications and trade under the ticker OPTU starting November 19. Opening Bell featured Evommune's IPO celebration; Closing Bell highlighted Arrow Electronics' 90th anniversary. Ashley Mastronardi handled the pre-market update.
  • Nio Stock Price Prediction 2025-2030: Tailwinds, Headwinds, and Long-Term Outlook
    November 6, 2025, 10:50 AM EST. NIO stock has faced tariff-driven volatility, hitting a multiyear low around $3.02, but rebounded and is up 67.2% year-to-date after a week of gains driven by record deliveries and higher revenue forecasts. A Singapore sovereign wealth fund lawsuit remains a headwind. Shares are 83.2% above six months ago, slightly ahead of the S&P 500; about half of 27 analysts rate it a buy, with a mean target of $6.91 and a high target of $9.02. Tailwinds include 600-mile range high-performance models and battery-swap technology, plus growing international presence. While the stock has been a two-story tale since its 2018 NYSE debut, the long-term outlook remains bullish, with 24/7 Wall St. projecting meaningful gains by 2030.
  • Under Armour Q3 Revenue Beats Estimates, But Margins and EBITDA Miss Highlight Tough Turnaround
    November 6, 2025, 10:47 AM EST. Under Armour (NYSE: UAA) posted Q3 CY2025 revenue of $1.33 billion, topping Street estimates of $1.31 billion but YoY sales fell 4.7%. Adjusted EPS of $0.04 beat consensus by $0.02, yet Adjusted EBITDA came in at $31.81 million vs $67.04 million expected, a sizable miss. The company guided full-year EPS at $0.04 midpoint, well below analysts' view. Operating margin compressed to 1.3% from 12.4% a year ago. Free Cash Flow was -$90.32 million (vs -$367.2 million a year earlier). Constant-currency revenue declined about 6% in the quarter, with modest signs of brand momentum in North America per CEO Kevin Plank. Analysts see revenue flat next year, implying a cautious near-term outlook for top-line growth.
  • Prestige Consumer Healthcare (PBH) Beats Q2 Earnings; Near-Term Outlook Cautious
    November 6, 2025, 10:44 AM EST. Prestige Consumer Healthcare (PBH) posted Q2 earnings of $1.07 per share, ahead of the Zacks Consensus of $0.97 and marking a +10.3% surprise. Revenue came in at $274.11 million, beating the consensus by 6.87% versus year-ago revenue of $283.79 million. Over the last four quarters, PBH has beaten EPS estimates three times. The stock has slid about 23.4% year to date, underperforming the S&P 500 (+15.6%). The firm carries a Zacks Rank #4 (Sell), signaling near-term underperformance unless management provides a positive earnings outlook on the call. For the coming quarter, current estimates are $1.23 on $294.9 million in revenue; FY guidance sits at $4.51 on $1.1 billion in revenue.
AI Frenzy Fuels Record Wall St Rally as Shutdown Drags On – Key Market News (Oct 6-7, 2025)
Previous Story

Stock Market Today 06.11.2025

Investors Beware: 7 Stocks to Avoid on October 22, 2025 Amid Alarming Warnings
Next Story

Michael Burry’s $1.1 Billion AI ‘Short’ Jolts Global Markets: Nvidia, Palantir Lead Tech Slide — What to Watch Today (Nov. 6, 2025)

Go toTop